Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Income from Continuing Operations (2022 - 2026)

Axsome Therapeutics' Income from Continuing Operations history spans 5 years, with the latest figure at 64542000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 8.63% to 64542000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 188293000.0, a 32.33% increase, with the full-year FY2025 number at 183204000.0, up 36.21% from a year prior.
  • Income from Continuing Operations hit 64542000.0 in Q1 2026 for Axsome Therapeutics, down from 28589000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for AXSM hit a ceiling of 11238000.0 in Q1 2023 and a floor of 98651000.0 in Q4 2023.
  • Historically, Income from Continuing Operations has averaged 56548882.35 across 5 years, with a median of 61241000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 71.64% in 2023 and later tumbled 508.27% in 2024.
  • Tracing AXSM's Income from Continuing Operations over 5 years: stood at 61241000.0 in 2022, then tumbled by 61.09% to 98651000.0 in 2023, then grew by 24.06% to 74912000.0 in 2024, then soared by 61.84% to 28589000.0 in 2025, then crashed by 125.76% to 64542000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for AXSM at 64542000.0 in Q1 2026, 28589000.0 in Q4 2025, and 47229000.0 in Q3 2025.